FREM1 promotes anlotinib resistance in non-small cell lung cancer through regulation of extracellular matrix organization
{{output}}
Background: Acquired resistance to anlotinib, a multi-targeted tyrosine kinase inhibitor, severely limits its long-term efficacy in non-small cell lung cancer (NSCLC). The extracellular matrix (ECM) is a critical component of the... ...
